Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Jupiter Wellness is a pre-revenue specialty pharmaceutical company developing cannabidiol (CBD)-based dermatological and wellness products. The company focuses on topical formulations targeting skin conditions and over-the-counter consumer wellness applications, operating in the emerging cannabinoid therapeutics space. With negative gross margins and minimal revenue, Jupiter is in early-stage commercialization, burning cash while attempting to establish market presence for its proprietary CBD delivery platforms.
Jupiter aims to generate revenue through direct-to-consumer and retail distribution of proprietary CBD-infused topical products, leveraging formulation expertise in cannabinoid delivery systems. The business model depends on achieving regulatory clarity for CBD products, establishing brand recognition in crowded wellness markets, and scaling manufacturing to achieve positive unit economics. Current negative gross margins indicate the company is selling below cost or incurring disproportionate production expenses relative to minimal sales, suggesting pricing power is nonexistent at this stage. Success requires transitioning from R&D-focused cash burn to commercial-scale operations with sustainable margins.
FDA regulatory developments or guidance on CBD product classifications and permissible health claims
Product launch announcements, retail distribution partnerships, or e-commerce sales traction metrics
Clinical trial results or efficacy data for dermatological applications of proprietary CBD formulations
Financing announcements, equity raises, or partnership deals that extend cash runway beyond current burn rate
Broader cannabis/CBD sector sentiment and regulatory momentum at federal or state levels
Regulatory uncertainty surrounding CBD products, including FDA enforcement discretion, permissible health claims, and potential reclassification that could restrict marketing or require costly clinical trials
Commoditization of CBD wellness market as barriers to entry remain low, with hundreds of competitors offering similar topical products without meaningful differentiation or intellectual property protection
Federal cannabis scheduling changes or state-level regulatory fragmentation that could disrupt supply chains, increase compliance costs, or limit addressable markets
Competition from well-capitalized consumer packaged goods companies (Unilever, P&G, L'Oréal) entering CBD skincare with established distribution, brand equity, and marketing budgets
Inability to differentiate proprietary formulations in market saturated with CBD topicals, leading to price-based competition that prevents margin expansion
Dependence on third-party manufacturing and ingredient suppliers in fragmented CBD supply chain, limiting quality control and cost advantages
Severe cash burn with -$0.0B operating cash flow and -7039% net margin requiring continuous equity financing, creating dilution risk for existing shareholders
Price/book ratio of 0.2x suggests market values company below tangible book value, indicating skepticism about asset realizability or going concern risks if funding becomes unavailable
Negative ROE of -163% and ROA of -64% reflect destruction of shareholder capital, with no clear path to profitability given current trajectory
moderate - CBD wellness and skincare products are discretionary consumer purchases, making demand sensitive to disposable income and consumer confidence. During economic downturns, non-essential health and beauty spending contracts. However, as a pre-revenue company, Jupiter's stock performance is more driven by clinical/regulatory milestones and financing conditions than current economic activity. Once commercialized, revenue would correlate with consumer spending trends in the $20B+ US wellness market.
High sensitivity through multiple channels. Rising rates increase discount rates applied to distant future cash flows, disproportionately compressing valuations for pre-revenue growth companies with no near-term profitability. Higher rates also tighten venture capital and growth equity financing conditions, making future capital raises more dilutive or difficult. With 10.59x current ratio suggesting adequate near-term liquidity but ongoing cash burn, the company will require additional financing where cost of capital directly impacts shareholder dilution. Additionally, rising rates reduce speculative appetite for high-risk biotech/cannabis plays.
Minimal direct credit exposure given 0.01 debt-to-equity ratio and apparent equity-financed capital structure. The company is not dependent on credit markets for operations. However, indirect exposure exists through consumer financing availability for discretionary purchases and overall risk appetite in growth equity markets that fund companies at this stage.
momentum/speculative - The 357% three-month return followed by -50% one-year return indicates extreme volatility attracting day traders and speculative investors betting on regulatory catalysts, partnership announcements, or sector rotation into cannabis plays. Not suitable for value investors given negative margins and uncertain path to profitability. Growth investors require credible commercialization roadmap currently absent. The warrant structure (JUPWW ticker) specifically attracts options-oriented traders seeking leveraged exposure to volatile underlying equity.
high - Pre-revenue biotech/cannabis companies with minimal float and binary regulatory/clinical outcomes exhibit extreme price volatility. Recent performance showing 357% gain in three months demonstrates susceptibility to momentum-driven rallies disconnected from fundamentals. Negative enterprise value (-0.2x EV/EBITDA) and minimal institutional ownership amplify volatility through low liquidity and retail-dominated trading.
